Cas:14098-24-9 Benzo-18-crown-6 manufacturer & supplier

Chemical Name:Benzo-18-crown-6

CAS.NO:14098-24-9

Synonyms:1,2-Ethylenebis(oxyethyleneoxyethyleneoxy)benzene;Benzo-18-crown-6;CROWN ETHER/BENZO-18-CROWN-6 FOR SYNTHES;B18C6;CROWN ETHER/BENZO-18-CROWN-6;2,3-Benzo-1,4,7,10,13,16-hexaoxaoctadec-2-ene;1,4,7,10,13,16-HEXAHYDROXY-16-ORTHOCYCLOPHANE;benzo-1,4,7,10,13,16-hexaoxacyclooctadecane;2,3-benzo-1,4,7,10,13,16-hexaoxacyclooctadec-2-ene;2,3,5,6,8,9,11,12,14,15-Decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecine;MFCD00062741;benzo-18-C-6;2,3,5,6,8,9,11,12,14,15-decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecin;1,4,7,10,13,16-Benzohexaoxacyclooctadecin, 2,3,5,6,8,9,11,12,14,15-decahydro-;Benzo-18-crown 6-Ether

Molecular Formula:C₁₆H₂₄O₆

Molecular Weight:312.358

HS Code:2932999099

Physical and Chemical Properties:

Melting point:42-45 °C(lit.)

Boiling point:451.8±45.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.456

PSA:55.38000

Exact Mass:312.157288

LogP:0.51

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,2-Ethylenebis(oxyethyleneoxyethyleneoxy)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzo-18-crown 6-Ether physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,2-Ethylenebis(oxyethyleneoxyethyleneoxy)benzene Use and application,benzo-1,4,7,10,13,16-hexaoxacyclooctadecane technical grade,usp/ep/jp grade.

Related News: The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems. rel-((3aR,4S,7R,7aS)-1,3-dioxo-3,3a,7,7a-tetrahydro-4,7-epoxyisobenzofuran-4(1H)-yl)methyl acetate manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. Dihydrobiflorin suppliers After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. methyl 2-methyl-4-oxopent-2-enoate vendor & factory After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease.,The CDC’s Advisory Committee on Immunization Practices (ACIP) decision on Thursday came after an hours-long discussion over a handful of Guillain-Barré syndrome (GBS) cases reported after J&J’s jab. The independent group of experts were also tasked with reviewing the need for booster shots, specifically for people with compromised immune systems.